Broussoflavonol F
Based on 1 Customer Validation
Broussoflavonol F is a potent dual inhibitor of the HER2-RAS-MEK-ERK signaling pathway and mushroom tyrosinase with an IC50 value of 82.3 μM. Broussoflavonol F downregulates the expression of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk proteins. Broussoflavonol F induces cell cycle arrest and apoptosis, and exhibits cytotoxicity in colon cancer cells. Broussoflavonol F inhibits endothelial proliferation, migration and tube formation, suppresses subintestinal vascular development, and reduces the mRNA levels of angiogenesis-associated genes.Broussoflavonol F can be used for colon cancer research.
For research use only. We do not sell to patients.
- Purity : 95.49%
- CAS No.: 162558-94-3
- Formula: C25H26O6
- Molecular Weight:422.47
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
IC50 & Target
[1]|
HER2 |
MEK |
Ras |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hep 3B2 | IC50 |
1.15 μM
Compound: 21
|
Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 36549116] |
| HepG2 | IC50 |
30.79 μM
Compound: 21
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 36549116] |
| Platelet | IC50 |
16.9 μM
Compound: 16
|
Antiplatelet activity against rabbit platelets assessed as arachidonic acid-induced platelet aggregation by turbidimetric method
Antiplatelet activity against rabbit platelets assessed as arachidonic acid-induced platelet aggregation by turbidimetric method
|
[PMID: 8864236] |
| Platelet | IC50 |
2.7 μM
Compound: 6
|
Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 20 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control
Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 20 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control
|
[PMID: 9358644] |
In Vitro
Broussoflavonol F (BFF) (0-20 μM; 24-48 h) exerts selective, concentration- and time-dependent cytotoxicity against HCT-116, LoVo, HT-29, SW480, and colon 26 colon cancer cells, with IC50 values of 6.64 μM (HCT-116) and 7.37 μM (LoVo) after 48 h, and is far less cytotoxic to PBMCs (IC50 = 47 μM)[1].
Broussoflavonol F (1.25-7.5 μM (HCT-116); 2.5-10 μM (LoVo); 24-48 h) effectively suppresses colony formation in HCT-116 and LoVo colon cancer cells after 24 h and 48 h treatment[1].
Broussoflavonol F (1.25-5 μM; 24-48 h) induces G0/G1 phase cell cycle arrest and reduces G2/M phase cell numbers in HCT-116 and LoVo colon cancer cells[1].
Broussoflavonol F (2.5-7.5 μM (HCT-116); 5-10 μM (LoVo); 24-48 h) significantly increases apoptosis in HCT-116 and LoVo colon cancer cells[1].
Broussoflavonol F (1.25-5 μM; 24-48 h) downregulates HER2, RAS, p-BRAF, p-MEK, and p-Erk protein expression (without altering total BRAF, MEK, or Erk) in HCT-116 and LoVo colon cancer cells after 24 h and 48 h treatment, inhibiting the HER2-RAS-MEK-ERK pathway[1].
Broussoflavonol F (0-20 μM; 48 h) exhibits cytotoxicity to HMEC-1 cells with an IC50 of 7.1 μM after 48 h treatment[1].
Broussoflavonol F (40 μM; 6 h) inhibits tube formation in HMEC-1 cells after 6 h incubation[1].
Broussoflavonol F (5 μM; 24 h) reduces cell motility in HMEC-1 cells after 24 h treatment[1].
Broussoflavonol F inhibits mushroom tyrosinase using L-tyrosine as substrate with an IC50 of 388.6 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human colon cancer HCT-116 and LoVo cells
-
Concentration:2.5, 5, 7.5, 10 μM
-
Incubation Time:24 h; 48 h
-
Result:Effectively suppressed colony formation in both HCT-116 and LoVo cells after 24 h and 48 h treatment.
Exhibited suppressive effects similar to the positive control 5-FU at 5 μM (HCT-116) and 7.5 μM (LoVo).
-
Cell Line:human colon cancer HCT-116 and LoVo cells
-
Concentration:1.25-5 μM
-
Incubation Time:24 h; 48 h
-
Result:Significantly arrested cells at the G0/G1 phase, accompanied by a decrease in cell number in the G2/M phase in both HCT-116 and LoVo cells after 24 h and 48 h incubation.
-
Cell Line:human colon cancer HCT-116 and LoVo cells
-
Concentration:2.5, 5, 7.5 μM (HCT-116); 5, 7.5, 10 μM (LoVo)
-
Incubation Time:24 h; 48 h
-
Result:Effectively increased the percentage of apoptotic cells in both HCT-116 and LoVo cells after 24 h and 48 h treatment.
-
Cell Line:human colon cancer HCT-116 and LoVo cells
-
Concentration:1.25, 2.5, 5 μM
-
Incubation Time:24 h; 48 h
-
Result:Significantly decreased the expression levels of HER2, RAS, p-BRAF, p-MEK, and p-Erk in both HCT-116 and LoVo cells after 24 h and 48 h treatment.
Did not regulate the expression levels of total BRAF, MEK, and Erk proteins.
-
Cell Line:human microvascular endothelial HMEC-1 cells
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Significantly decreased cell motility after 24 h treatment.
In Vivo
Broussoflavonol F (5-10 mg/kg; i.p.; daily; 21 days) at 10 mg/kg suppresses in vivo colon tumor growth, reduces tumor cell proliferation and angiogenesis, and downregulates the HER2-RAS-MEK-ERK pathway in HCT116 xenograft-bearing mice without inducing measurable liver or muscle toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tg(fli1:EGFP)y1 transgenic line (24 hours post-fertilization embryos)[1]
-
Dosage:1.25 µM, 2.5 µM, 5 µM
-
Administration:immersion; continuous; 48 hours
-
Result:Significantly reduced the length of subintestinal vessels (SIVs) in a concentration-dependent manner at 2.5 µM and 5 µM (p < 0.0001).
Significantly suppressed mRNA expressions of angiogenesis-related genes NRP1a, PDGFba, PDGFRb, KDR, and FLT1 at 5 µM.
-
Animal Model:Male nude mice (6-8 weeks old, 25-30 g; subcutaneous xenograft of human HCT116 colon cancer cells)[1]
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:i.p.; daily; 21 days
-
Result:Significantly reduced final tumor weight relative to control at 10 mg/kg.
Downregulated tumor tissue expressions of RAS, p-BRAF, p-MEK, and p-Erk proteins at 5 mg/kg and 10 mg/kg.
Decreased the number of Ki-67-positive (proliferation) and CD31-positive (angiogenesis) cells in tumor sections at 10 mg/kg.
Caused no significant changes in plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), or lactate dehydrogenase (LDH) levels, indicating no obvious liver or muscle toxicity.
Chemical Information
-
CAS No. 162558-94-3
-
Appearance Solid
-
Molecular Weight 422.47
-
Formula C25H26O6
-
Color Light yellow to yellow
-
SMILES
O=C1C(O)=C(C2=CC=C(O)C(C/C=C(C)\C)=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (236.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3670 mL | 11.8352 mL | 23.6703 mL | 59.1758 mL |
| 5 mM | 0.4734 mL | 2.3670 mL | 4.7341 mL | 11.8352 mL | |
| 10 mM | 0.2367 mL | 1.1835 mL | 2.3670 mL | 5.9176 mL | |
| 15 mM | 0.1578 mL | 0.7890 mL | 1.5780 mL | 3.9451 mL | |
| 20 mM | 0.1184 mL | 0.5918 mL | 1.1835 mL | 2.9588 mL | |
| 25 mM | 0.0947 mL | 0.4734 mL | 0.9468 mL | 2.3670 mL | |
| 30 mM | 0.0789 mL | 0.3945 mL | 0.7890 mL | 1.9725 mL | |
| 40 mM | 0.0592 mL | 0.2959 mL | 0.5918 mL | 1.4794 mL | |
| 50 mM | 0.0473 mL | 0.2367 mL | 0.4734 mL | 1.1835 mL | |
| 60 mM | 0.0395 mL | 0.1973 mL | 0.3945 mL | 0.9863 mL | |
| 80 mM | 0.0296 mL | 0.1479 mL | 0.2959 mL | 0.7397 mL | |
| 100 mM | 0.0237 mL | 0.1184 mL | 0.2367 mL | 0.5918 mL |